Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab for Platelet Transfusion Refractoriness
NCT05284032Phase 1Terminated
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isatuximab in Platelet transfusion refractoriness (PTR). Primary endpoint: Percent panel-reactive antibodies at 120 days. Started Nov 2022; status: terminated.
02
Drugs
isatuximab
03
Conditions
Platelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on NCT05284032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284032.